- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04089722
Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissue in the "Bra Strap Fat" Region
Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissue in the Anterior and Posterior Aspect of the Axilla "Bra Strap Fat"
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The efficacy and safety of deoxycholic acid injections to dissolve adipose tissue in the submental area have been extensively evaluated. Deoxycholic acid injections have also been used successfully off-label to dissolve adipose tissues in other body areas. Our clinical experience in addition to a few case reports have shown the effectiveness and safety of deoxycholic acid injections to dissolve the adipose tissue in the anterior and posterior aspect of the axilla or the so called "brassiere strap fat" (BSF).
This is a single-center, prospective, single-arm, single-blind trial study.
This study is expected to benefit the existing literature by potentially adding a new non-invasive injectable treatment to a condition of excessive adipose tissue in the anterior and posterior aspect of the axilla that until now could only be treated with invasive surgery.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10022
- Juva Skin & Laser Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult female age 18-65
- Subject satisfaction rating score of 0 or 1
- Clinician reported BSF rating score of 2, 3 or 4
- Patient reported BSF rating score of 2, 3 or 4
- Able to follow study instructions and likely to complete all required visits, as assessed by the Investigator.
- Willing to withhold additional aesthetic therapies to the proposed treatment area.
- Negative urine pregnancy test
- Willing to use acceptable methods of contraception throughout the study
- Sign an IRB-approved Informed Consent Form prior to any study-related procedures being performed.
Exclusion Criteria:
- History of any intervention to treat BSF (eg, liposuction, surgery, lipolytic agents)
- History of trauma associated with the axillary or upper back area
- Severe Skin Laxity Grade or other anatomical feature as assessed within 28 d before randomization, for which reduction in BSF may, in the judgment of the investigator, result in an aesthetically unacceptable outcome
- Evidence of any cause of enlargement in the upper back/ axillary roll (eg, tumors, lipomas) other than localized BSF
- BMI greater than 35 kg/m2
- A result on coagulation tests (prothrombin time, partial thromboplastin time) obtained within 28 d before randomization indicating the presence of any clinically significant bleeding disorder
- Any medical condition (eg, respiratory, cardiovascular, hepatic, neurologic disease, thyroid dysfunction) that would interfere with assessment of safety or efficacy or compromise the patient's ability to undergo study procedures or give informed consent
- History of sensitivity to any components of the study drug
- History of sensitivity to topical or local anesthetics (eg, lidocaine, benzocaine, procaine)
- Pregnancy
- Lactation
- Presence of infection at the injection sites
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Open-Label: Deoxycholic Acid Injections
Deoxycholic Acid Injections (dose strength: 2 mg/cm2) via subcutaneous injections into posterior and/or anterior axillary roll adiposity.
Patients will receive 10 mL or less (≤100 mg) of study drug per treatment administered in 0.2-mL injections with a 30-gauge, 0.5-in needle attached to a 1-mL syringe at 1.0-cm spacing using a customized grid.
Up to 6 treatments (30 ± 7 days apart) will be permitted, but fewer can be allowed because of efficacy (insufficient BSF to inject, patient satisfaction with treatment) or safety/tolerability concerns.
|
The active ingredient in KYBELLA® is synthetic deoxycholic acid.
Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of Anterior/Posterior Axilla Fat
Time Frame: 6 months
|
Composite improvements of 1 or more grades in BSF observed on both the Clinician- and Patient-Reported BSF Rating Scales
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bruce E Katz, MD, Juva Skin & Laser Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 60E56
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deoxycholic Acid
-
Kythera BiopharmaceuticalsBayerCompletedModerate or Severe Submental FullnessGermany, France, Belgium, Spain, United Kingdom
-
Kythera BiopharmaceuticalsCompletedPhase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)Moderate or Severe Submental FullnessUnited Kingdom, Canada, Australia
-
AllerganTerminated
-
Kythera BiopharmaceuticalsCompletedEfficacy | Safety | Moderate to Severe Convexity of Submental FatUnited States
-
AllerganCompleted
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States, Canada
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessUnited States, Canada
-
Kythera BiopharmaceuticalsCompleted
-
Kythera BiopharmaceuticalsCompletedModerate or Severe Submental FullnessAustralia, Canada, United Kingdom